Nivolumab
Disease Related To Hematopoietic Stem Cell Transplant
Explore 55 assets in Disease Related To Hematopoietic Stem Cell Transplant →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
St. Petersburg State Pavlov Medical University
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03600155CT.gov Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01822509CT.gov Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Disease Related To Hematopoietic Stem Cell Transplant
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | St. Petersburg State Pavlov Medical University | P2 | B · 60 |
| Busulfanum | Institute of Hematology & Blood Diseases Hospital, China | P3 | BBB |
| Cyclophosphamide | The First Affiliated Hospital of Soochow University | P3 | BBB |
| Nivestim | National Cancer Institute (NCI) | P2/3 | BBB |
| Rituximab | M.D. Anderson Cancer Center | P2 | BBB |
| Decitabine | Chinese PLA General Hospital | P4 | BBB |
| Cyclosporin A | The First Affiliated Hospital of Soochow University | P4 | BB |
| Tacrolimus | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | P3 | BB |
| Thiotepa | medac GmbH | P2 | BB |
+42 more in the Disease Related To Hematopoietic Stem Cell Transplant cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Disease Related To Hematopoietic Stem Cell Transplant. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-disease-related-to-hematopoietic-stem-cell-transplant-56530
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →